TABLE 1.
The baseline characteristics of the patients treated with immunotherapy are shown below.
| Variable | Number of patients; n = 155 (%) |
|---|---|
| Site of primary tumor | |
| Head and neck cancer | 48 (31) |
| Lung cancer | 76 (49) |
| Adenocarcinoma | 59 |
| Squamous cell carcinoma | 13 |
| Small cell lung cancer | 4 |
| Others (Renal cell carcinoma, urothelial carcinoma, malignant mesothelioma) | 31 (20) |
| Median age in years | 57.16 (21.79–85.63) 95% CI |
| Sex | |
| Male | 119 (76.8) |
| Female | 36 (23.2) |
| ECOG performance status | |
| 0–1 | 102 (66.7) |
| 2–3 | 51 (32.0) |
| Missing data | 2 (1.3) |
| Brain metastasis | 13 (8.4) |
| Immunotherapy received in median which line (overall data). | 2nd (Range, 1–9) |